Day: May 14, 2025

Generated record Q1 Contribution ex-TAC and programmatic revenue, driven by 40% year-over-year CTV revenue growth, alongside a 95% year-over-year increase in Adjusted EBITDA Trading structure simplification has driven higher trading volume as well as increased analyst and investor interest Completed $50 million Ordinary Share repurchase program and launched a new and ongoing $50 million repurchase program in April 2025 Hosting investor day on May 22, 2025 NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) — Nexxen International Ltd. (NASDAQ: NEXN) (“Nexxen” or the “Company”), a global, flexible advertising technology platform with deep expertise in data and advanced TV, announced today its financial results for the three months ended March 31, 2025. Q1 2025 Financial HighlightsRecord Q1 Contribution ex-TAC of $75.0 million, up 8% year-over-year Record...

Strong performance despite volatile economic environment MISSISSAUGA, Ontario, May 14, 2025 (GLOBE NEWSWIRE) — KP Tissue Inc. (KPT) (TSX: KPT) reports the Q1 2025 financial and operational results of KPT and Kruger Products Inc. (Kruger Products). Kruger Products is Canada’s leading manufacturer of quality tissue products for the Consumer market (Cashmere®, Purex®, SpongeTowels®, Scotties®, White Swan® and BonterraTM) and the Away-From-Home (AFH) market and continues to grow in the U.S. Consumer tissue business with the White Cloud® brand and premium private label products. KPT currently holds a 12.3% interest in Kruger Products. Kruger Products Q1 2025 Business and Financial HighlightsRevenue was $546.1 million in Q1 2025 compared to $479.4 million in Q1 2024, an increase of $66.7 million or 13.9%. Adjusted EBITDA1 was...

Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this yearORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) on track with data expected across all three indications this year with first-in-class potential in NT2 and IH ORX142 on track to initiate first-in-human studies for the treatment of neurological and neurodegenerative disorders with clinical data in acutely sleep-deprived healthy volunteers planned for this year ORX489 advancing in IND-enabling studies for the treatment of neuropsychiatric disordersBOSTON and LONDON, May 14, 2025 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported financial results...

9% year-over-year revenue growth Affirms sequential quarterly revenue growth target throughout 2025 MIGDAL HAEMEK, Israel, May 14, 2025 (GLOBE NEWSWIRE) — Tower Semiconductor (NASDAQ/TASE: TSEM) reports today its results for the first quarter ended March 31, 2025. First Quarter of 2025 Results OverviewRevenues for the first quarter of 2025 were $358 million as compared to $327 million for the first quarter of 2024, representing 9% year-over-year revenue growth. Gross profit and operating profit for the first quarter of 2025 were $73 million and $33 million, respectively, as compared to gross profit and operating profit of $73 million and $34 million in the first quarter of 2024, respectively. Gross and operating profits remain similar since the positive impact of the $31 million revenue increase was offset by the fixed costs of...

PHOENIX, May 14, 2025 (GLOBE NEWSWIRE) — Mesa Air Group, Inc. (NASDAQ: MESA) (“Mesa” or the “Company”) today reported fourth quarter and fiscal full-year 2024 financial and operating results. Fourth Quarter Fiscal 2024 Update:Total operating revenues of $115.3 million Pre-tax loss of $24.5 million, net loss of $24.9 million, or $(0.60) per diluted share Adjusted net loss1 of $0.1 million2, or $(0.00) per diluted share Adjusted EBITDAR1 of $18.2 million Operated at a 99.88% controllable completion factor3Republic Transaction:Entered into definitive agreement with Republic Airways Holdings Inc. (“Republic”) for an all-stock merger to create a leading regional airline company Mesa’s operations will support a new 10-year CPA with United Airlines, Inc. (“United”) as part of transactionAsset Transactions Over Past Six Months:Completed...

Revenues for First Quarter of 2025 of $44.0 Million, Representing a 17% Year-over-Year Increase First Quarter Adjusted EBITDA of $11.6 Million, Up 54% Year-over-Year Strong Financial Position to Accelerate Growth Through M&A and/or In-licensing Opportunities Announced Expansion of Plasma Collection Operations with Opening of New Site in San Antonio, Texas Launched Comprehensive Post-Marketing Research Program of CYTOGAM® Reiterating Full Year 2025 Guidance, Representing Double Digit Profitable Growth Year-over-Year Conference Call and Live Webcast Today at 8:30am ETREHOVOT, Israel and HOBOKEN, N.J., May 14, 2025 (GLOBE NEWSWIRE) — Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived...

With clinical momentum across its pipeline, atai strengthens its position as a leader in potentially transformative psychedelic mental health treatmentsAnticipate topline data midyear from the Phase 2b clinical trial of BPL-003 in patients with treatment-resistant depression (TRD) – the largest controlled trial of mebufotenin and the first and only such trial to investigate mebufotenin in the U.S. Dosed the first patient in the exploratory Phase 2 study of EMP-01 (oral R-MDMA) for the treatment of social anxiety; topline data anticipated in Q1’26 Continued enrollment in Elumina, a Phase 2 study of VLS-01 (buccal film DMT) in patients with TRD; topline data are anticipated in Q1’26Cash, cash equivalents, short-term securities, and public equity holdings expected to fund operations into 2027 NEW YORK and BERLIN, May 14, 2025 ...

NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) — Chicago Atlantic BDC, Inc. (“LIEN” or the “Company”) (NASDAQ: LIEN), a specialty finance company that has elected to be regulated as a business development company, today announced its financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights and Subsequent EventsTotal gross investment income of $11.9 million Net investment income of $7.6 million, or $0.34 per weighted average share outstanding Total investment portfolio of $289.3 million at fair value Net asset value (“NAV”) per share was $13.19 on March 31, 2025 Declared a dividend of $0.34 per share for the quarter ended March 31, 2025, paid on April 11, 2025 to shareholders of record as of March 28, 2025 Declared a dividend of $0.34 per share for the quarter ended June 30, 2025 payable on July 11,...

First quarter revenues of $46.5 million, in line with previous guidance First quarter GAAP net loss of $5.1 million; non-GAAP net income of $0.6 million Continued to generate cash from operations, demonstrating disciplined execution Reported annual recurring revenue from AIC contracts of $14.5 million, reflecting strong initial adoption of this new business modelROSH-HA`AYIN, Israel, May 14, 2025 (GLOBE NEWSWIRE) —  Kornit Digital Ltd. (“Kornit” or the “Company”) (Nasdaq: KRNT), a global leader in sustainable, on-demand, digital fashion and textile production technologies, today reported results for the first quarter ended March 31, 2025. “We delivered to our commitments in Q1, even as we operated in an uncertain macro environment,” said Ronen Samuel, Kornit’s Chief Executive Officer. “The apparel industry is undergoing significant...

– Oxylanthanum carbonate (OLC) New Drug Application (NDA) for hyperphosphatemia in chronic kidney disease patients on dialysis under review by FDA with PDUFA target action date of June 28, 2025; ongoing commercial planning in preparation for anticipated commercial launch in late 2025 – New data from patient surveys and patient-reported outcomes studies highlight adherence challenges for patients with hyperphosphatemia on dialysis and emphasize the market potential of OLC LOS ALTOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the three months ended March 31, 2025, and provided a business update. “We are making incredible strides as we prepare...